Join Ropes & Gray’s life sciences and health care attorneys on a four-part podcast series exploring regulatory, compliance and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2023. This first episode will focus on key developments from 2022 that we expect to continue to be significant in 2023. Topics discussed include the Inflation Reduction Act, the Food and Drug Omnibus Reform Act (FDORA), possible legislative action related to orphan drug exclusivity, and the full resumption of domestic and international FDA inspections.
RopesTalk